Claims
- 1. A thieno[3,2-b][1,5]benzodiazepine of the formula ##STR30## or an acid addition salt thereof, wherein R.sup.1 and R.sup.2 independently represent hydrogen, C.sub.1-4 alkyl, halogen, C.sub.1-4 haloalkyl, nitro, amino, C.sub.1-4 alkoxy, C.sub.1-4 alkylthio or a group of the formula --SO.sub.2 N(R.sup.4).sub.2 where R.sup.4 is C.sub.1-4 alkyl; wherein R.sup.5 is a group of the formula ##STR31## wherein R.sup.6 is hydrogen, phenyl, halo phenyl, C.sub.1-4 alkyl, C.sub.1-4 carbalkoxy or --(CH.sub.2).sub.n OH where n is 2 or 3; and wherein the thiophene ring is unsubstituted or is substituted by a C.sub.1-4 alkyl group.
- 2. A thieno[3,2-b][1,5]benzodiazepine of claim 1 wherein R.sup.1 and R.sup.2 are optional substituents at the 6- or 7-positions of the thieno[1,5]benzodiazepine system.
- 3. A thieno[3,2-b][1,5]benzodiazepine of claim 1, wherein R.sup.1 is a 6- or 7-halo or trifluoromethyl substituent when R.sup.2 is hydrogen.
- 4. A thieno[3,2-b][1,5]benzodiazepine of claim 1 wherein R.sup.6 is methyl.
- 5. An acid addition salt according to claim 1 which is pharmaceutically-acceptable.
- 6. A pharmaceutical formulation according to claim 7 in the form of a capsule, tablet or injection solution.
- 7. A pharmaceutical formulation comprising as an active ingredient a chemotherapeutically effective amount of a compound of the formula: ##STR32## or a pharmaceutically-acceptable salt thereof, wherein R.sup.1 and R.sup.2 independently represent hydrogen, C.sub.1-4 alkyl, halogen, C.sub.1-4 haloalkyl, nitro, amino, C.sub.1-4 alkoxy, C.sub.1-4 alkylthio or a group of the formula --SO.sub.2 N(R.sup.4).sub.2 where R.sup.4 is C.sub.1-4 alkyl; wherein R.sup.5 is a group of the formula: ##STR33## wherein R.sup.6 is hydrogen, phenyl, halo phenyl, C.sub.1-4 alkyl, C.sub.1-4 carbalkoxy or --(CH.sub.2).sub.n OH where n is 2 or 3; and wherein the thiophene ring is unsubstituted or is substituted by a C.sub.1-4 alkyl group.
- 8. A method of treating an animal suffering from, or susceptible to, disorders of the CNS, which comprises administering to the animal a chemotherapeutically effective amount of a compound of the formula: ##STR34## or a pharmaceutically-acceptable salt thereof, wherein R.sup.1 and R.sup.2 independently represent hydrogen, C.sub.1-4 alkyl, halogen, C.sub.1-4 haloalkyl, nitro, amino, C.sub.1-4 alkoxy, C.sub.1-4 alkylthio or a group of the formula --SO.sub.2 N(R.sup.4).sub.2 where R.sup.4 is C.sub.1-4 alkyl; wherein R.sup.5 is a group of the formula: ##STR35## wherein R.sup.6 is hydrogen, phenyl, halo phenyl, C.sub.1-4 alkyl, C.sub.1-4 carbalkoxy or --(CH.sub.2).sub.n OH where n is 2 or 3;
- and wherein the thiophene ring is unsubstituted or is substituted by a C.sub.1-4 alkyl group.
- 9. The compound of claim 1 which is 7-fluoro-10-(4-methyl-1-piperazinyl)-4H-thieno[3,2-b][1,5]benzodiazepine or a pharmaceutically-acceptable salt thereof.
Priority Claims (1)
Number |
Date |
Country |
Kind |
51240/74 |
Nov 1974 |
GBX |
|
Parent Case Info
This is a division of application Ser. No. 633,895, filed Nov. 20, 1975, now abandoned.
US Referenced Citations (6)
Divisions (1)
|
Number |
Date |
Country |
Parent |
633895 |
Nov 1975 |
|